Letters/Comments
AHA letters and comments provide insight to legislators and policymakers about laws and regulations important to the healthcare field.
AHA letter to CMS regarding their attention to improving health plan prior authorization processes through appropriate standardization.
AHA's comments on the Centers for Medicare & Medicaid Services’ final rule with comment period on program integrity enhancements to the provider enrollment process. The agency indicates that this final rule is part of its ongoing effort to protect the Medicare program from improper behavior.
AHA urges the Centers for Medicare & Medicaid Services to release long-awaited guidance to help hospitals and health systems interpret Medicare’s conditions of participation, or develop alternative approaches to keep them informed and updated about compliance.
AHA letter to the Congressional Telehealth Caucus in support of the CONNECT for Health Act of 2019.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices voiced strong support for the Mitigating Emergency Drug Shortages Act (S.2723), which includes provisions recommended by a…
AHA's comments to House leaders on the Lower Drug Costs Now Act (H.R. 3), legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.
The AHA recognizes that SAMHSA is statutorily constrained in making structural amendments to the regulations under 42 CFR Part 2; however, because the proposed rule would not change the basic framework of Part 2, which significantly impedes the robust sharing of patient information necessary for…
The AHA urges Senate appropriators to support federal funding for research and education to reduce violence in communities
The AHA and six other organizations comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
The AHA appreciates the opportunity to comment on the Drug Enforcement Administration’s proposed notice on aggregate production quotas for schedule I and II controlled substances.